Reva Basho

1.2k total citations
35 papers, 514 citations indexed

About

Reva Basho is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Reva Basho has authored 35 papers receiving a total of 514 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 16 papers in Cancer Research and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Reva Basho's work include Cancer Immunotherapy and Biomarkers (16 papers), Cancer Treatment and Pharmacology (10 papers) and Breast Cancer Treatment Studies (9 papers). Reva Basho is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), Cancer Treatment and Pharmacology (10 papers) and Breast Cancer Treatment Studies (9 papers). Reva Basho collaborates with scholars based in United States, Spain and United Kingdom. Reva Basho's co-authors include Cuiwei Liu, Xiaojiang Cui, Yanxia Zhao, Derick Okwan‐Duodu, Daniel D. Karp, Michael Z. Gilcrease, Stacy L. Moulder, Vicente Valero, Rashmi K. Murthy and Funda Meric‐Bernstam and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Reva Basho

32 papers receiving 508 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Reva Basho United States	11	316	144	117	112	61	35	514
Benedetta Conte Italy	12	331 1.0×	171 1.2×	193 1.6×	183 1.6×	38 0.6×	41	574
Pooja Advani United States	17	358 1.1×	102 0.7×	219 1.9×	107 1.0×	22 0.4×	67	799
Claudio Flores Peru	11	278 0.9×	85 0.6×	85 0.7×	136 1.2×	17 0.3×	41	493
Nahid Nafissi Iran	14	151 0.5×	165 1.1×	174 1.5×	95 0.8×	30 0.5×	64	526
Andrew Ip United States	8	196 0.6×	60 0.4×	83 0.7×	58 0.5×	14 0.2×	66	415
Faye Turner United Kingdom	13	263 0.8×	76 0.5×	250 2.1×	71 0.6×	45 0.7×	15	529
Mona S. Abdellateif Egypt	12	159 0.5×	105 0.7×	141 1.2×	42 0.4×	52 0.9×	48	418
Katherine Enright Canada	10	412 1.3×	216 1.5×	119 1.0×	138 1.2×	19 0.3×	36	627
Giuseppa Scandurra Italy	11	243 0.8×	72 0.5×	113 1.0×	91 0.8×	86 1.4×	47	498
Wylie Hosmer United States	7	175 0.6×	82 0.6×	200 1.7×	100 0.9×	93 1.5×	10	590

Countries citing papers authored by Reva Basho

Since Specialization

Citations

This map shows the geographic impact of Reva Basho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reva Basho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reva Basho more than expected).

Fields of papers citing papers by Reva Basho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reva Basho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reva Basho. The network helps show where Reva Basho may publish in the future.

Co-authorship network of co-authors of Reva Basho

This figure shows the co-authorship network connecting the top 25 collaborators of Reva Basho. A scholar is included among the top collaborators of Reva Basho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reva Basho. Reva Basho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Eunice, Preet K. Dhillon, Peter Lambert, Anna Cheng, & Reva Basho. (2024). PIK3CA testing and treatment patterns among patients with metastatic breast cancer in US community clinical practice.. Journal of Clinical Oncology. 42(16_suppl). e13059–e13059.

Ho, Alice Y., Stephen L. Shiao, Jonathan Chen, et al.. (2024). PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer. Journal of Clinical Oncology. 42(36). 4282–4293. 6 indexed citations

Swain, Sandra M., Carlos H. Barrios, Reva Basho, et al.. (2024). Abstract PO2-19-09: INAVO122: a Phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients with PIK3CA-mutated, HER2-positive advanced breast cancer. Cancer Research. 84(9_Supplement). PO2–19. 1 indexed citations

Basho, Reva, et al.. (2023). Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer. Current Oncology Reports. 25(7). 689–698. 10 indexed citations

Walsh, David, Sumana Srivatsa, Renee D. George, et al.. (2023). Individualized treatment estimates to inform on personalized cancer care decisions for treatment selection and treatment management.. Journal of Clinical Oncology. 41(16_suppl). e13571–e13571. 1 indexed citations

Dillon, Patrick M., Reva Basho, Hyo S. Han, et al.. (2023). Abstract OT1-03-06: Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress). Cancer Research. 83(5_Supplement). OT1–3. 3 indexed citations

McArthur, Heather L., Stephen L. Shiao, Reva Basho, et al.. (2023). Neoadjuvant HER2-targeted therapy ± immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial.. Journal of Clinical Oncology. 41(16_suppl). TPS634–TPS634. 1 indexed citations

Liu, Cuiwei, Jielin Wei, Ekihiro Seki, et al.. (2022). Breast cancer liver metastasis: Pathogenesis and clinical implications. Frontiers in Oncology. 12. 1043771–1043771. 17 indexed citations

McArthur, Heather L., David B. Page, Reva Basho, et al.. (2022). Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial.. Journal of Clinical Oncology. 40(16_suppl). TPS624–TPS624. 3 indexed citations

10.

Cooper, Benjamin T., Steven J. Chmura, Jason J. Luke, et al.. (2022). TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design.. Journal of Clinical Oncology. 40(16_suppl). TPS2698–TPS2698. 14 indexed citations

11.

Kim, Isaac, Venkatesh Rajamanickam, Brady Bernard, et al.. (2021). A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy. Frontiers in Oncology. 11. 635237–635237. 14 indexed citations

12.

McArthur, Heather L., Stephen L. Shiao, Scott Karlan, et al.. (2021). Abstract PS12-09: Pre-operative pembrolizumab (Pembro) with radiation therapy (RT) in patients with operable triple-negative breast cancer (TNBC). Cancer Research. 81(4_Supplement). PS12–9. 5 indexed citations

13.

Liu, Cuiwei, Yanxia Zhao, Derick Okwan‐Duodu, Reva Basho, & Xiaojiang Cui. (2020). COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biology and Medicine. 17(3). 519–527. 131 indexed citations

14.

Cortés, Javier, Sami Diab, Reva Basho, et al.. (2020). 357TiP SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer. Annals of Oncology. 31. S393–S393. 5 indexed citations

15.

Crystal, Jessica S., Jeffrey Johnson, Sung‐Jin Kim, et al.. (2020). Adjuvant endocrine therapy is associated with improved overall survival in elderly hormone receptor-positive breast cancer patients. Breast Cancer Research and Treatment. 184(1). 63–74. 4 indexed citations

16.

Han, Hyo S., Carlos Alemany, Ursa Brown‐Glaberman, et al.. (2019). SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer.. Journal of Clinical Oncology. 37(15_suppl). TPS1110–TPS1110. 26 indexed citations

17.

Basho, Reva, Clinton Yam, Michael Z. Gilcrease, et al.. (2018). Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. The Oncologist. 23(11). 1300–1309. 45 indexed citations

18.

Basho, Reva, Michael Z. Gilcrease, Rashmi K. Murthy, et al.. (2016). Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer. JAMA Oncology. 3(4). 509–509. 152 indexed citations

19.

Basho, Reva, et al.. (2015). Clinical Applications and Limitations of Next-Generation Sequencing. 11(3). 10 indexed citations

20.

Basho, Reva, Débora De Melo Gagliato, Naoto T. Ueno, et al.. (2015). Clinical outcomes based on multigene profiling in metastatic breast cancer patients.. Journal of Clinical Oncology. 33(15_suppl). 1524–1524. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact